MST1 and diabetes mellitus: The effect of the strong MST1 inhibitor neratinib (the most widely controlled), documented in basic studies, is the basis for further research aimed at implementing a new diabetes treatment formula based on the maintenance of β-cell survival and function and the elimination of hyperglycemia [44,101].